摘要
目的探讨靶向引经报使药对维持性血液透析患者骨代谢的影响。方法选择2021年2月-2023年2月肾病科门诊就诊及住院治疗的维持性血液透析患者180例为研究对象,根据经络辨证随机分为6组,即对照组2组,治疗组4组。对照组:肾经、肝经组均在一般基础治疗上,口服骨化三醇,治疗组在一般基础治疗及口服骨化三醇基础上大剂量药引子肾经、肝经分别口服川芎牛膝20g、配伍自拟补肾壮骨方;小剂量药引子肾经、肝经组分别口服川牛膝10g,配伍自拟补肾壮骨方,各组均完成3个月治疗,比较各组骨代谢水平及安全性。结果6组干预3个月后骨代谢水平得到提升;观察肾经大剂量组、观察肝经大剂量组、观察肾经小剂量组和观察肝经小剂量组PTH、P及ALP水平低于对照肾经组和对照肝经组(P<0.05);Ca高于对照肾经组和对照肝经组(P<0.05);6组用药过程中全身反应、消化道、心血管、呼吸系统不良反应发生率无统计差异(P>0.05)。结论靶向引经报使药用于维持性血液透析患者中,改善患者骨代谢水平,且治疗安全性较高,值得推广应用。
Objective To explore effect of targeted guiding action drugs on bone metabolism of maintenance hemodialysis patients.Methods The paper chose 180 maintenance hemodialysis patients with outpatient and inpatient treatment in nephrology department from February 2021 to February 2023 as subjects,and divided them into 6 groups randomly based on meridian differentiation(i.e.control group 2,treatment group 4).Control group:kidney channel group and the liver channel group took Calcitriol orally on the basis of general basic treatment andtreatment group took 20g Chuanxiong Niuxi orally on the basis of general basic treatment and oral Calcitriol on the kidney channel and the liver channel respectively,in combination with the self-designed kidney tonifying and bone strengthening prescription;kidney channel group and liver channel group of low-dose drug Yinzi took 10 g of Cyathula officinalis orally,which were combined with the self prepared kidney tonifying and bone strengthening prescription.Each group completed three months of treatment and compared the level of bone metabolism and safety of each group.Results After 3 months of intervention,the bone metabolism level of the six groups was improved;levels of PTH,P and ALP in the high-dose group of the kidney meridian,high-dose group of the liver meridian,lowdose group of the kidney meridian and low-dose group of the liver meridian were lower than control kidney meridian group and control liver meridian group(P<0.05).Ca was higher than control kidney meridian group and control liver meridian group(P<0.05).There was no statistically significant difference in the incidence of systemic reactions,gastrointestinal,cardiovascular and respiratory adverse reactions during the medication process among the six groups(P>0.05).Conclusion Targeted guiding action drugs can improve bone metabolism levels of maintenance hemodialysis patients with high treatment safety,which is worthy of promotion and application.
作者
魏涛
曾明源
杨禄颜
WEI Tao;ZENG Mingyuan;YANG Luyan(Nephrology Department,Maoming City Traditional Chinese Medicine Hospital,Maoming,Guangdong 525000)
出处
《智慧健康》
2023年第19期154-157,共4页
Smart Healthcare
基金
茂名市科技计划项目《靶向引经报使药对维持性血液透析患者骨代谢的影响》(项目编号:2021079)。
关键词
靶向引经报使药
维持性血液透析
骨代谢
安全性
Targeted guiding action drugs
Maintenance hemodialysis
Bone metabolism
Safety
